AtheroGenics AGI-1067 NDA On Track For H1’07; AstraZeneca Funding ARISE Extension
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
AtheroGenics is on track to submit an NDA for its atherosclerosis therapy AGI-1067 in the first half of 2007, the company said during a second-quarter investor call